News stories about Celator Pharmaceuticals (NASDAQ:CPXX) have trended positive on Friday, Accern reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Celator Pharmaceuticals earned a daily sentiment score of 0.27 on Accern’s scale. Accern also gave headlines about the company an impact score of 43.1625908168226 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

ILLEGAL ACTIVITY NOTICE: “Celator Pharmaceuticals (CPXX) Getting Favorable News Coverage, Study Finds” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/08/19/celator-pharmaceuticals-cpxx-earning-favorable-news-coverage-analysis-finds-updated-updated-updated.html.

Celator Pharmaceuticals Company Profile

Celator Pharmaceuticals, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in developing products to improve patient outcomes in cancer. The Company’s technology platform, CombiPlex, enables the design and evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity.

Insider Buying and Selling by Quarter for Celator Pharmaceuticals (NASDAQ:CPXX)

Receive News & Stock Ratings for Celator Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celator Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.